Meropenem: Evaluation of a new generation carbapenem

International Journal of Antimicrobial Agents

Volumn 8, Issue 2, 1997, Pages 73-92

  Blumer, Jeffrey L ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

antibacterial; carbapenem; imipenem; meropenem; lactamases

Indexed keywords

BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; IMIPENEM; MEROPENEM;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CLINICAL TRIAL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; ENTEROBACTERIACEAE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SEPTICEMIA; SKIN INFECTION; URINARY TRACT INFECTION;

EID: 0030942075     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(96)00347-0     Document Type: Article

References (107)

1. Fukasawa M, Sumita Y, Harabe ET, et al. Stability of meropenem and effect of 1-β-methyl substitution on its stability in the presence of renal dehydropeptidase I. Antimicrob Agents Chemother 1992;36:1577-1579.
2. Birnbaum J, Kahan FM, Kropp H, Macdonald S. Carbapenems, a new class of β-lactam antibiotics. Discovery and development of imipenem cilastatin. Am J Med 1985;78(S-6A):3-21.
3. Sunagawa M, Matsumura H, Inoue T, Fukasawa M, Kato M. A novel carbapenem antibiotic, SM-7338 structure-activity relationships. J Antibiot 1990;XLIII:519-532.
4. Kitzis MD, Acar JF, Gutmann L. Antibacterial activity of meropenem against Gram-negative bacteria with a permeability defect and against staphylococci. J Antimicrob Chemother 1989;24(S-A):125-132.
5. Satake S, Yoshihara E, Nakae T. Diffusion of β-lactam antibiotics through liposome membranes reconstituted from purified porins from the outer membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 1990;34:685-690.
6. Edwards JR. Meropenem: a microbiological overview. J Antimicrob Chemother 1995;36(Suppl A):1-17.
7. Sumita Y, Fukasawa, Okuda T. Comparison of two carbapenems. SM-7338 and imipenem: affinities for penicillin-binding proteins and its release from these proteins and morphological changes. J Antibiot 1990;XLII:314-320.
8. Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995;50:73-101.
9. Chen HY, Yuan M, Ibrahim-Elmagboul IB, et al. National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother 1995;35:521-534.
10. García-Rodriguez JA, García Sánchez JE, García García MI, et al. Antibiotic susceptibility profile of Xanthomonas maltophilia. In vitro activity of β-lactam β-lactamase combinations. Diagn Microbiol Infect Dis 1991;14:239-243.
11. Liñares J, Alonso T, Pérez JL, et al. Decreased susceptibility of penicillin-resistant pneumococci to twenty-four β-lactam antibiotics. J Antimicrob Chemother 1992;30:279-288.
12. Bauernfeind A, Jungwirth R, Schweighart S. In vitro activity of meropenem, imipenem and penem HRE 664 and ceftazidime against clinical isolates from West Germany. J Antimicrob Chemother 1989;24(S-A):73-84.
13. Jones RN, Barry AL, Thornsberry C. In vitro studies of meropenem. J Antimicrob Chemother 1989;24(S-A):9-29.
14. Ellis LC, Levin JM, Koenig GI, et al. In vitro susceptibility of ceftazidime (CAZ) resistant aerobic Gram-negative rods (GNR): a comparison of meropenem (MER) with other antimicrobial agents. Abstracts from the 93rd General Meeting of the American Society for Microbiology, Atlanta, 16-20 May 1993:3. Abstract A16.
15. Voutsinas D, Mavroudis T, Avlamis A, et al. In vitro activity of meropenem against multiresistant Pseudomonas aeruginosa compared with other antipseudomonal antimicrobials. J Antimicrob Chemother 1989;24(S-A):143-147.
16. Grecka P, Giamarellos-Bourboulis EJ, Giamarellou H. Comparison of the in vitro activity of meropenem versus imipenem against ceftazidime resistant Pseudomonas aeruginosa nosocomial pathogens. 9th Mediterranean Congr Chemother, Milan, 12-17 June 1994:58. Abstract 030.
17. Turner PJ, Edwards JR. The activity of meropenem and comparators against Pseudomonas aeruginosa strains isolated throughout Europe. Program and Abstracts of the 18th Int Congr Chemother. Stockholm, 27 June-2 July 1993:285. Abstract 975.
18. King A, Boothman C, Phillips I. Comparative in vitro activity of meropenem on clinical isolates from the United Kingdom. J Antimicrob Chemother 1989;24(S-A):31-45.
19. Spangler SK, Jacobs MR, Appelbaum PC. Susceptibility of 177 penicillin-susceptible and -resistant pneumococci top FK 037, cefpirome, cefepime, ceftriaxone, cefotaxime, ceftazidime, imipenem, biapenem, meropenem and vancomycin. Antimicrob Agents Chemother 1994;38:898-900.
20. Sarubbi F, Franzus B, Verghese A. Comparative activity of meropenem (SM-7338) against major respiratory pathogens and amikacin-resistant nosocomial isolates. Eur J Clin Microbiol Infect Dis 1992;11:65-68.
21. Jorgensen JH, Maher LA, Howell AW. Activity of meropenem against antibiotic-resistant or infrequently encountered Gram-negative bacilli. Antimicrob Agents Chemother 1991;35:2410-2414.
22. Constantine CE, Warren, Brown DJF. Activity of meropenem compared with other agents against Gram-negative bacilli with reduced susceptibility to ciprofloxacin. Spanish J Chemother 1992;5(S-4):73-77.
23. Azadian BS, Talboys CA, Roberts AP. Sensitivity of ciprofloxacin resistant Acinetobacter spp. to meropenem. Med Mal Infect 1993;23(2):109-110.
24. Geflan MS, Grogan JT. Comparative activity of meropenem, piperacillin/tazobactam, cefoperazone sulbactam and miscellaneous other agents against ciprofloxacin, cefoperazone and/or amikacin-resistant Gram-negative rods. Abstracts of the Annual Meeting of the American Society for Microbiology, Dallas, 5-9 May 1991: A18.
25. Shiekh W, Pitkin DH, Nadler H. Antibacterial activity of meropenem and selected comparative agents anaerobic bacteria at seven North American Centers. Clin Infect Dis 1992;16(S-4):S361-S366.
26. Murray PR, Niles AC. In vitro activity of meropenem (SM-7338), imipenem and 5 other antibiotics against anaerobic clinical isolates. Diagn Microbiol Infect Dis 1990;13:57-61.
27. Wantabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991;25:891-902.
28. Livermore DM. Carbapenemases: the next generation of β-lactamases? ASM News 1993;59:129-135.
29. Livermore DM. Mechanisms of resistance to β lactam antibiotics. Scand J Infect Dis 1991;(S)78:7-16.
30. Margaret BS, Drusano GL, Standiford HC. Emergence of resistance to carbapenem antibiotics in Pseudomonas aeruginosa. J Antimicrob Chemother 1989;24 (S-A):161-167.
31. Sanders CC, Sanders Jr WE, Thompson KS, Iaconis JP. Meropenem: activity against Gram-negative bacteria and interactions with β-lactamases. J Antimicrob Chemother 1989;24(S-A):187-196.
32. Yang Y, Livermore DM. Interactions of meropenem with class 1 chromosomal β-lactamases. J Antimicrob Chemother 1989;24(S-A):207-217.
33. Piddock LJV, Turner HL. Activity of meropenem against imipenem-resistant bacteria and selection in-vitro of carbapenem-resistant Enterobacteriaceae. Eur J Clin Microbiol Infect Dis 1992;11:1186-1191.
34. Ferrara A, Grassi G, Grassi FA, Picioni PD, Gialdroni Grassi G. Bactericidal activity of meropenem and interactions with other antibiotics. J Antimicrob Chemother 1989;24(S-A):239-250.
35. Ferrara A, Dos Santos C, Cimbro M. High-level gentamicin-resistant enterococci: in vitro activity of double and triple combinations of antimicrobial drugs. Chemotherapy 1996;42:37-46.
36. Wise R, Ashby JP, Andrews JM. The antibacterial activity of meropenem in combination with gentamicin or vancomycin, J Antimicrob Chemother 1989;24(S-A):233-238.
37. Edwards JR, Turner PJ, Nairn K. Activity of meropenem in combination with vancomycin and teicoplanin against methicillin-susceptible and -resistant staphylococci. Int Congr Chemother, Stockholm, 27 June 2 July 1993. 285. Abstract 973.
38. Debbia EA, Milinari G, Pesce A, Schito G-C. Antibacterial activity of meropenem, alone and in combination with other drugs, and post-antibiotic effect. In: Abstracts of the 8th Mediterranean Congr Chemother, Athens, Greece. 24-29 May 1992: 259-260. Abstract 344.
39. Drusano GL, Ryan PA, Standiford HC, et al. Integration of selected pharmacokinetic and microbiological properties of three β-lactam antibiotics: a hypothesis for rational comparison. Rev Inf Dis 1984;6:357-363.
40. Walker R, Andres D, Conklin J, Ebert S, Craig W. Pharmacodynamic activities of meropenem in an animal infection model. Program and Abstracts of the 34th Interscience Conf Antimicrob Agents Chemother. Orlando. 2-5 October 1994:147. Abstract A91.
41. Craig WA. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broadspectrum cephalosporins. Diagn Microbiol Infect Dis 1995;22:89-96.
42. Drusano GL, Hutchison M. The pharmacokinetics of meropenem. Scand J Infect Dis 1995;(S-96):11-16.
43. Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males. Eur J Clin Microbiol Infect Dis 1991;10:85-88.
44. Keller E, Fecht H, Bohler J, et al. Single-dose kinetics of imipenem-cilastatin during continuous arteriovenous haemofiltration in intensive care patients. Nephrol Dial Transplant 1989;4:640-645.
45. Bax RP, Bastain W, Featherstone A, Wilkinson DM, Hutchison M, Haworth SJ. The pharmacokinetics of meropenem in volunteers. J Antimicrob Chemother 1989;24(S-A):311-320.
46. Kelly HC, Hutchison M, Haworth SJ. A comparison of the pharmacokinetics of meropenem after administration by intravenous injection over 5 min and intravenous infusion over 30 min. J Antimicrob Chemother 1995;36(S-A):35-42.
47. Hutchison M, Faulkner KL, Turner PJ, et al. A compilation of meropenem tissue distribution data. J Antimicrob Chemother 1995;36(S-A):43-56.
48. Harrison P, Moss SR, Featherstone A, Fowkes AG, Sanders AM, Case DE. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 1989;24(S-A):265-277.
49. Blumer JL, Reed MD, Kearns GL, et al. Sequential, single-dose pharmacokinetic evaluation of meropenem in hospitalized infants and children. Antimicrob Agents and Chemother 1995;39:1721-1725.
50. Martinkova J, de Groot R, Chladek J, et al. Meropenem pharmacokinetics in pre-term and full-term neonates Program and Abstracts of the 7th Eur Congr Clin Microbiol Infect Dis. Vienna, March 26-30 1995:133. Abstract 686.
51. Ljungberg B, Nilsson-Ehle I. Pharmacokinetics of meropenem and its metabolite in young and elderly healthy men. Antimicrob Agents Chemother 1992;36:1437-1440.
52. Christensson BA, Nilsson-Ehle I, Hutchison M, Haworth SJ, Oeqvist B, Norrby SR. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment. Antimicrob Agents Chemother 1992;36:1532-1537.
53. Leroy A, Fillastre JP, Borsa-Lebase F, et al. Pharmacokinetics of meropenem (ICI 194,660) and its metabolite (ICI 213,689) in healthy subjects and in patients with renal impairment. Antimicrob Agents Chemother 1992;36:2794-2798.
54. Leroy A, Fillastre JP, Etienne I, Borsa-Lebas F, Humbert G. Pharmacokinetics of meropenem in subjects with renal insufficiency. Eur J Clin Pharmacol 1992;45:535-538.
55. Chimata M, Nagase M, Suzuki Y, et al. Pharmacokinetics of meropenem in patients with various degrees of renal function, including patients with end-stage renal disease. Antimicrob Agents Chemother 1993;37:229-233.
56. Thyrum Per T, Yeh C, Birmingham B, Lasseter K. The pharmacokinetics of meropenem in subjects with liver disease. Clin Infect Dis 1997. In press.
57. Christensson BA, Ljungberg B, Eriksson L, Nilsson-Ehle I. Pharmacokinetics of meropenem in cystic fibrosis patients. Proc Abstracts 34th Interscience Conf Antimicrob Agents Chemother, Orlando, 1994. Abstract A73.
58. Mouton JW, van den Anker JN. Meropenem clinical pharmacokinetics. Clin Pharmacokinet 1995;28:275-286.
59. Blumer JL. Carbapenems in paediatrics. Scand J Infect Dis 1995;(S-96):38-44.
60. Schuler D, Meropenem Paediatric Study Group. Safety and efficacy of meropenem in hospitalised children: randomised comparison with cefotaxime, alone and combined with metronidazole or amikacin. J Antimicrob Chemother 1995;36(S-A):99-108.
61. Hara K, Sakamoto S, Komori K, et al. A comparative study of meropenem and imipenem cilastatin sodium in bacterial pneumonia (in Japanese). Chemotherapy (Tokyo) 1992;40:1343-1364.
62. Hara K, Kono S, Koga H, et al. A comparative study of meropenem and imipenem cilastatin sodium in chronic respiratory tract infections (in Japanese). Chemotherapy (Tokyo) 1992;40:1426-1450.
63. Hara K, Kono S, Koga H, et al. Dose-finding study of meropenem in bacterial pneumonia (in Japanese). Chemotherapy (Tokyo) 1992;40(S-1):447-463.
64. Sieger B, Geckler R. A comparison of meropenem and ceftazidime plus tobramycin in the treatment of hospital-acquired lower respiratory infections. Program and Abstracts of the 33rd Interscience Conf Antimicrob Agents Chemother, New Orleans, 1993:236. Abstract 640.
65. Mouton YJ, Beuscart C. Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995;36(S-A):145-156.
66. Hamacher J, Vogel F, Lichey J, et al., on behalf of the COPD-study group. Treatment of acute bacterial exacerbation of chronic obstructive pulmonary disease in hospitalised patients a comparison of meropenem and imipenem/cilastatin. J Antimicrob Chemother 1995;36(S-A):121-134.
67. Rizzato G, Montemurro L, Fanti D, et al. Meropenem versus imipenem: relationship between microbiological parameters and clinical outcome in lower respiratory tract infections. Curr Ther Res 1993;54:731-752.
68. Romanelli G, Cravarezza P, Ragni G, Franchino L. Meropenem IV in lower respiratory tract infections: a multicenter study. Farmaci and terapia 1995;12:1-9.
69. Romanelli G, Cravarezza P. Italian Intramuscular Meropenem Study Group. Intramuscular meropenem in the treatment of bacterial infections of the urinary and lower respiratory tracts. J Antimicrob Chemother 1995;36(S-A):109-120.
70. Byrne S, Maddison J, Connor P, et al. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonus spp. infections in cystic fibrosis patients. J Antimicrob Chemother 1995;36(S-A):135-144.
71. Colardyn F. Meropenem versus imipenem/cilastatin in the treatment of serious bacterial infections. Program and Abstracts of the 35th Interscience Conf Antimicrob Agents Chemother, San Francisco, 17-20 Sept 1995: 327. Abstract LM3.
72. Webb AK. The treatment of pulmonary infection in cystic fibrosis. Stand J Infect Dis 1995;(S-96):24-27.
73. Ciofu O, Jensen T, Pressler T, et al. Meropenem is efficient for treatment of chronic lung infection with resistant P. aeruginosa and B. cepacia in cystic fibrosis (CF). Final Program and Abstracts of the 19th Int Congr Chemother, Montreal, July 16-21 1995. Can J Infect Dis 1995;6(S-C):352C. Abstract 2055.
74. Ciofu O, Jensen T, Pressler T, et al. Meropenem is efficient for treatment of chronic lung infection with resistant P. aeruginosa and B. cepacia in cystic fibrosis (CF). Final Program and Abstracts of the 19th Int Congr Chemother, Montreal, July 16-21 1995. Can J Infect Dis 1995;6(S-C):352C. Abstract 2055.
75. Wilson SE. Carbapenems: monotherapy in intra-abdominal sepsis. Scand J Infect Dis 1995;(S-96):28-33.
76. Condon RE, Walker AP, Sirinek KR, et al. Meropenem versus tobramycin plus clindamycin for treatment of intraabdominal infections: results of a prospective, randomized, double-blind clinical trial. Clin Infect Dis 1995;21:544-550.
77. Huizinga WKJ, Warren BL, Baker LW, et al. Antibiotic monotherapy with meropenem in the surgical management of intra-abdominal infections. J Antimicrob Chemother 1995;36 (S-A):179-190.
78. Brismar B, Malmborg AS, Tuncrall G, et al. Meropenem versus imipenem cilastatin in the treatment of intra-abdominal infections. Report from a Swedish Study Group. J Antimicrob Chemother 1995;35:139-148.
79. Geroulanos SJ, Meropenem Study Group. Meropenem versus imipenem cilastatin in intra-abdominal infections requiring surgery. J Antimicrob Chemother 1995;36(S-A):191-206.
80. Kanellakopoulou K, Giamerellou H, Papadothomakos P, et al. Meropenem versus imipenem cilastatin in the treatment of intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 1993;12:449-453.
81. Dagan R, Velghe L, Rodda JL, et al. Penetration of meropenem into the cerebrospinal fluid of patients with meningitis. J Antimicrob Chemother 1994;34:175-179.
82. Nairn K, Shepherd GL, Edwards JR. Efficacy of meropenem in experimental meningitis. J Antimicrob Chemother 1995;35(S-A):73-84.
83. Schmutzhard E, Williams KJ, Vukmirovits G, et al. and the Meropenem Meningitis Study Group. A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of meningitis in adults. J Antimicrob Chemother 1995;36(S-A):85-98.
84. Klugman KP, Dagan R, and the Meropenem Meningitis Study Group. A randomised comparison of meropenem with cefotaxime for the treatment of bacterial meningitis. Antimicrob Agents Chemother 1995;39:1140-1146.
85. Donnelly JP, Horrevorts AM, Sauermwein RW, De Pauw BE. High dose meropenem in meningitis due to Pseudomonas aeruginosa. Lancet 1992;339:1117.
86. Chmelik V, Gutvirth J. Meropenem treatment of post-traumatic meningitis due to Pseudomonas aeruginosa. Lancet 1993;2:922-923.
87. Wong VK, Wright HT, Ross LA, Mason MH, Inderlied DB, Kim KS. Imipenem cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J 1991;10:122-125.
88. Calandra G, Lydick E, Carrigan J, Weiss L, Guess H. Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem cilastatin. Am J Med 1988;84:911-918.
89. Solberg CO, Sjursen H. Safety and efficacy of meropenem in patients with septicaemia: a randomised comparison with ceftazidime, alone or combined with amikacin. J Antimicrob Chemother 1995;36(S-A):157-166.
90. Cox CE, Holloway WJ, Geckler RW. A multicenter comparative study of meropenem and imipenem/cilastatin in the treatment of complicated urinary tract infections in hospitalized patients. Clin Infect Dis 1995;21:86-92.
91. Naber KG. Efficacy of meropenem in both complicated and uncomplicated urinary tract infection: comparison with ceftazidime [abstract]. 8th Mediterranean Congr Chemother, May 22-24, 1992.
92. Nichols RL, Smith JW, Geckler RW, et al. Meropenem versus imipenem/cilastatin in the treatment of hospitalised patients with skin and soft tissue infections. South Med J 1995;88:397-404.
93. Meropenem Study Group of Leuven, London and Nijmegen. Equivalent efficacies of meropenem and ceftazidime as empirical monotherapy of febrile neutropenic patients. J Antimicrob Chemother 1995;36:185-200.
94. Cometta A, Calandra T, Gaya H, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob Agents Chemother 1996;40(5):1108-1115.
95. Norrby SR, Vandercam B, Louie T, et al. Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis 1987;52(S):65-78.
96. Winston DJ, Ho WG, Bruckner DA, Champlin RE. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. Ann Intern Med 1991;115:849-859.
97. Freifeld AG, Walsh T, Marshall D, et al. Monotherapy for fever and neutropenia in cancer patients: a randomized comparison of ceftazidime versus imipenem. J Clin Oncol 1995;13:165-176.
98. Hemsell D, Martens M. A comparison of meropenem and clindamycin-gentarnicin in the treatment of obstetric and gynaecologic infections. 9th Mediterranean Congr Chemother, 1994:100. Abstract.
99. Topham JC, Murgatroyd LB, Jones DV, Goonetilleke URP, Wright J. Safety evaluation of meropenem in animals: studies on the kidney. J Antimicrob Chemother 1989;24(S-A):287-306.
100. Patel JB, Giles RE, Meropenem: evidence of lack of proconvulsive tendency in mice. J Antimicrob Chemother 1989;24(S-A):307-309.
101. Hori S, Kanemitsu K, Shimada J. Epileptogenic activity of meropenem, a new carbapenem. A comparative study on epileptogenic activity of carbapenems and β-lactams. Abstract 301. 32nd Interscience Conf Antimicrob Agents Chemother. Anaheim. 11-14 October 1992.
102. Sunagawa M, Matsumura H, Fukasawa M. Structure-activity relationships of carbapenem and penem compounds for the convulsive property. J Antibiot 1992;XLV:1983-1985.
103. De Sarro A, Ammendola D, Zappala M, et al. Relationship between structure and convulsant properties of some β-lactam antibiotics following intracerebroventricular microinjection in rats. Antimicrob Agents Chemother 1995;39:232-237.
104. Norrby SR, Newell PA, Faulkner KL, Lesky W. Safety profile of meropenem: international clinical experience based on the first 3125 patients treated with meropenem. J Antimicrob Chemother 1995;36(S-A):207-223.
105. Wang C, Calandra GB, Azix MA, Brown KR. Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience. Rev Infect Dis 1985;7(S):S528-S536.
106. Day IP, Goudie J, Nishiki K, Williams PD. Correlation between in vitro and in vivo models of proconvulsive activity with the carbapenem antibiotics, biapenem, imipenem/cilastatin and meropenem. Toxicol Lett 1995;76:239-243.
107. Bergan T, Nord CE, Thorsteinsson SB. Effect of meropenem on the intestinal microflora. Eur J Clin Microbiol Infect Dis 1991;3:475-527.